Tyr204
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr204  -  SOCS3 (mouse)

Site Information
VNGHLDSyEKVTQLP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450446

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 2 ) , western blotting ( 1 , 2 )
Relevant cell line - cell type - tissue:
3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 2 ) , BaF3 ('B lymphocyte, precursor') ( 1 ) , COS (fibroblast) ( 2 ) , liver ( 1 ) , lymph node ( 1 ) , spleen ( 1 )

Upstream Regulation
Putative in vivo kinases:
JAK2 (human) ( 1 )
Kinases, in vitro:
INSR (human) ( 2 )
Treatments:
GH ( 2 ) , insulin ( 2 ) , LIF ( 2 ) , ruxolitinib ( 1 )

Downstream Regulation
Effects of modification on biological processes:
cell cycle regulation ( 1 )

References 

1

Funakoshi-Tago M, et al. (2019) Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant. Cytokine 123, 154753
31255914   Curated Info

2

Peraldi P, et al. (2001) Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. J Biol Chem 276, 24614-20
11325969   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.